Arrowhead prices offering at $104M; FDA clears rectal delivery device from Hospi;

> Arrowhead ($ARWR) priced an underwritten offering of 5.5 million shares at $18.95 per share. The RNAi therapeutic company expects to pull in about $104 million. Release

> The FDA cleared Hospi Corporation's Macy Catheter device for rectal administration of liquid medication. More

The Wall Street Journal highlighted Mir Imran's Rani Therapeutics, which, backed by Google ($GOOG), is developing a robotic pill to replace injections. Profile

Suggested Articles

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.

Alexion's 100 mg/ml Ultomiris formulation is expected to slash infusion times by about 60% and bodes well for a planned subcutaneous version, too.